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OBJECTIVES This prospective study was designed to evaluate the effect of joint determination of two
important contrary biomarkers—homocysteine and glutathione peroxidase (GPx)-1—on
cardiovascular risk stratification.
BACKGROUND Homocysteine plasma levels have been associated with cardiovascular risk. Experimental data
suggest that antioxidative GPx-1 activity modulates cardiovascular risk associated with
homocysteine.
METHODS In 643 patients with coronary artery disease, we performed a prospective study to assess the
risk of homocysteine plasma levels and GPx-1 activity on long-term cardiovascular risk with
a median follow-up of 7.1 years.
RESULTS Both homocysteine and GPx-1 were among the strongest univariate predictors of future
cardiovascular risk, even after adjustment for cardiovascular confounders. Homocysteine levels
were significantly elevated in individuals with future cardiovascular events (15.4 vs. 13.4
mol/l; p 0.0001); GPx-1 activity was lower (45.3 13.1 vs. 50.2 11.0 U/g hemoglobin;
p  0.0001). In patients with GPx-1 activity below the median value, homocysteine plasma
levels above the median were associated with a 3.2-fold (95% confidence interval 1.8 to 5.6;
p  0.0001) increase in cardiovascular risk, whereas it lost its independent risk prediction in
individuals with increased antioxidative capacity, as reflected by high GPx-1 activity. In
contrast to single determination, combined assessment revealed a significant increase in the
area under the curve of cardiovascular risk predictive models from 0.72, including traditional
risk factors to 0.75 and also including homocysteine levels and GPx-1 activity.
CONCLUSIONS Plasma homocysteine levels and GPx-1 activity are complementary in identifying individuals
at high cardiovascular risk. Joint determination of both biomarkers provides substantial
information on top of classic risk factors in cardiovascular risk assessment. (J Am Coll
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.02.053Cardiol 2005;45:1631–7) © 2005 by the American College of Cardiology Foundation
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sild to moderate elevation of total plasma homocysteine
as been postulated to be causally involved in the develop-
ent of atherosclerotic disease (1–3). However, there are
till conflicting findings whether or not homocysteine inde-
endently adds to the predictive value over and above that
btained from traditional risk factors (4,5).
Mild to moderate elevation of homocysteine plasma levels
s frequent (6). The adverse effects of homocysteine on
ndothelial function and atherosclerotic lesion progression
ay be triggered, among other potential pathophysiologic
echanisms (7), by increased oxidative stress, leading to a
ecrease in vascular nitric oxide bioactivity (8). In mamma-
ian cells, glutathione is involved in oxidant defense, mainly
y the most abundant and ubiquitous of the glutathione
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nd a grant of the “Fondation de France” (240013/2002004994).f
Manuscript received October 30, 2004; revised manuscript received January 25,
005, accepted February 8, 2005.eroxidase enzymes—glutathione peroxidase-1 (GPx-1)
9). Homocysteine not only leads to the formation of
eactive oxygen species (ROS) but also, as recently shown,
nhibits the expression of this antioxidant enzyme (10). On
he other hand, in vitro models could demonstrate that the
verexpression of GPx-1 can restore the normal endothelial
henotype in hyperhomocysteinemic states (11). Thus,
aseline erythrocyte levels of the antioxidant enzyme GPx-1
merges as a defense marker rather than as an indicator of
xidative stress. Recently, baseline levels of the erythrocyte
Px-1 activity have been shown to be inversely related to
uture cardiovascular risk in patients with coronary artery
isease (CAD) during a five-year follow-up (12).
So far, the predictive value of homocysteine concen-
ration has not been evaluated while taking into account
Px-1 activity, which may enlighten the ongoing con-
roversy. Hence, the present study was carried out to
valuate whether homocysteine levels and GPx-1 activity
dd independent information for cardiovascular risk
tratification on top of that obtained from traditional risk
actors and whether the activity of GPx-1 as an oxidative
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omocysteine.
ETHODS
tudy population. Between November 1996 and Decem-
er 1997, 732 patients referred to the Department of
edicine II of the Johannes Gutenberg-University Mainz
or suspected CAD were enrolled in the AtheroGene regis-
ry. Fourteen patients with acute myocardial infarction (MI)
nd 75 patients in whom GPx-1 activity could not be
etermined immediately were excluded from the present
nalysis. Therefore, the final study cohort consisted of 643
atients: 133 of them with symptoms of unstable and 510
ith symptoms of stable angina. In all patients, coronary
ngiography was performed. In 558 patients, relevant CAD
i.e., 30% stenosis in at least one major coronary artery)
as detected. The study has been described in detail
lsewhere (12). Briefly, exclusion criteria were evidence of
emodynamically significant valvular heart disease, surgery,
r trauma within the previous month, known cardiomyop-
thy, known malignant diseases, febrile conditions, or oral
nticoagulant therapy within the previous four weeks. Dia-
etes mellitus was diagnosed in patients with dietary treat-
ent or antidiabetic medication or current fasting blood
ugar 125 mg/dl, hypertension in patients who had
eceived antihypertensive treatment or had been diagnosed
s hypertensive (blood pressure 160/90 mm Hg). Smok-
ng was classified as current, past (stopped between 4
eeks and 40 years), or never smoking.
Among the 643 patients, 639 (99.4%) were followed for
median of 7.1 years (maximum 7.6; AtheroGene follow-up
f 2 years). There were 84 deaths from cardiovascular
auses, 33 deaths from causes not related to heart disease,
nd 28 nonfatal MIs. Information on the cause of death or
linical events was obtained from hospital or general prac-
itioner charts.
The study was approved by the ethics committee of the
niversity of Mainz. Participation was voluntary, and each
tudy subject gave written, informed consent.
aboratory methods. Blood was drawn under standardized
onditions before coronary angiography. The GPx-1 activ-
ty was determined in washed red blood cells obtained
mmediately from whole blood anticoagulated with EDTA.
emolyzed cells were stored frozen for up to one week,
Abbreviations and Acronyms
AUC  area under the curve
CAD  coronary artery disease
CI  confidence interval
GPx-1  glutathione peroxidase-1
HR  hazard ratio
hs-CRP  high-sensitivity C-reactive protein
MI  myocardial infarction
ROS  reactive oxygen specieshich does not lead to changes in enzyme activity. Then, lPx-1 was measured as described (13), with minor modi-
cations (Randox, United Kingdom). Intra- and interassay
oefficients of variation were 6.7% and 9.9%, respectively.
ipid serum levels were measured immediately by routine
ethods (total cholesterol and triglycerides, Roche Diag-
ostics, Mannheim, Germany; high-density lipoprotein
holesterol, Rolf Greiner Biochemica, Flacht, Germany;
nd low-density lipoprotein cholesterol calculated by the
riedewald formula). Fibrinogen was determined immedi-
tely by the derived method.
For all other biomarkers described here, plasma and
erum were stored at 80°C until analysis, which was
erformed after a mean of 1.5 years storage time. Homo-
ysteine was determined by high-pressure liquid chroma-
ography (interassay coefficient of variation 7.1%), selenium
y carbon furnace atomic absorption spectrometry with
eeman compensation, as previously described (14), and
-reactive protein (CRP) by a highly sensitive, latex
article-enhanced immunoassay (detection range of 0.1 to
0 mg/l, Roche Diagnostics, Mannheim, Germany; inter-
ssay coefficient of variation 1.0% at 15 mg/l and 6.5% for
alues 4 mg/l).
tatistical methods. Mean levels and proportions of base-
ine cardiovascular risk factors were calculated for study
articipants, according to GPx-1 activity below or above the
edian value. The significance of mean differences between
he two groups was assessed by the Student t test, and the
ignificance of proportion differences was tested by the
hi-square statistic. Variables with a skewed distribution—
bsolute value of skewness 1—were presented as median
alues, and the Wilcoxon rank-sum test was applied. In all
urvival analyses, the combined end point was death from
ardiovascular causes and nonfatal MI. Patients who died
rom other causes were censored at the time of death.
azard ratios (HRs) for future coronary events, according
o quartiles of homocysteine and GPx-1 activity, were
stimated by Cox regression analysis, adjusting for potential
onfounders. Three adjusted models were constructed. The
Rs were determined for quartiles 2 to 4 in comparison
ith the lowest category, and the p value across the quartiles
as calculated by use of the Wald test (1 degree of
reedom). First, we adjusted for age and gender, and second,
or other cardiovascular predictors. In the final model, all
otential clinical and therapeutic variables, as well as con-
ounders, were included. We further evaluated the com-
ined role of GPx-1 activity and homocysteine on cardio-
ascular risk, and therefore classified the study participants
nto four groups according to Gpx-1 activity and homocys-
eine plasma levels below and above their respective median
alues. The homogeneity of homocysteine effects by GPx-1
ctivity levels on cardiovascular risk was formally tested by
ncluding a term of interaction between homocysteine and
Px-1 levels considered as dichotomous variables in the
ox regression model. The four cumulative event plots
btained by combining high/low Gpx-1 activity and high/
ow homocysteine concentration were estimated by the
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May 17, 2005:1631–7 Homocysteine, GPx-1, and Cardiovascular Riskaplan-Meier method and compared using the log-rank
est. The discriminative value of different predictive models
as estimated by the area under the (receiver operating)
urve (AUC) obtained from the C statistic in a logistic
egression model, including all traditional risk factors and
lso the plasma levels of homocysteine, serum creatinine,
nd GPx-1 activity. The HRs and their 95% confidence
ntervals (CIs) are reported. The p values are two-sided; p
.05 was considered to be significant. All computations
ere carried out with SPSS Version 10.07 (SPSS Inc.,
hicago, Illinois).
ESULTS
he mean age of the study population was 61.7  10.1
ears; 72.2% were male patients. The GPx-1 activity
howed a mean (SD) level of 49.3  11.5 and a median
25th/75th percentile) of 48.3 (42.2/56.3) U/l hemoglobin
Hb). The respective data for homocysteine concentrations
n the overall study population showed a median (25th/75th
ercentile) of 13.7 (11.3/16.8) mol/l. Baseline character-
stics of the study population according to median GPx-1
ctivity are provided in Table 1. The major determinants of
Px-1 activity were, before all, smoking and, to a lesser
xtent, gender and hyperlipidemia of the classic risk factors,
s well as homocysteine and selenium levels of the humoral
Table 1. Baseline Characteristics of the Overal
Value (48.3 U/g Hb) of Glutathione Peroxidas
Variable
<4
(
Age (yrs) 6
Male gender (%)
Classic risk factors
BMI (kg/m2) 2
History of diabetes (%)
History of hypertension (%)
Smokers (%)
Hyperlipidemia
Homocysteine metabolism
Homocysteine (mol/l) 14.4
Vitamin B12 (pg/ml) 390
Folic acid (ng/ml) 7.0
GPx-1 metabolism
Selenium (ng/ml) 7
Clinical variables
Multivessel disease (2) (%)
Left ventricular ejection fraction (%)
(n  539)
6
Medication
Statin medication (%)
Beta-blocker (%)
Renal function
Creatinine (mg/dl)
Inflammation
hs-CRP (mg/l) 3.9
Fibrinogen (mg/dl) 33
Data are presented as the percentage of patients or mean va
skewed variables. Smoking status comprises current and form
BMI  body mass index; GPx-1  glutathione peroxid
protein.arkers. pThe GPx-1 activity was lower in the subgroup of patients
ith future cardiovascular events (45.3  13.1 vs. 50.2 
1.0 U/g Hb; p  0.0001). Likewise, the median homo-
ysteine plasma concentration was elevated in the event
roup in comparison with event-free individuals (15.4
13.1/21.1] vs. 13.4 (11.0/16.2) mol/l; p  0.0001). In a
ox proportional hazards model, the upper quartile of
omocysteine was associated with a 3.0 (95% CI 1.35 to
.66) increase in risk after adjustment for most potential
linical and therapeutic variables, including creatinine and
Px-1 (Table 2). The upper quartile of creatinine (1.19
g/dl) itself was also independently associated with future
ardiovascular risk in a fully adjusted model (Table 2). The
nverse relationship between GPx-1 activity and future
ardiovascular risk also remained highly significant after a
ong-term follow-up period of 7.1 years.
The interaction between these two variables on cardio-
ascular risk was investigated by estimating the HR associ-
ted with high homocysteine, according to GPx-1 activity.
n patients with GPx-1 activity above the median value
48.3 U/g Hb), the association between homocysteine
bove the median (13.7 mol/l) and future cardiovascular
vents did not reach a significant level (HR 1.7, 95% CI 0.9
o 3.3; p  0.10). By contrast, in patients with GPx-1
ctivity below the median value, elevated homocysteine
dy Population According to the Median
aseline Levels
/g Hb
321)
>48.3 U/g Hb
(n  322) p Value
9.8 61.7  10.3 0.97
3 68.4 0.03
3.8 27.0  3.3 0.28
8 13.5 0.15
1 71.4 0.16
8 51.0 0.0001
9 63.5 0.03
5/17.9) 13.5 (11.3/16.0) 0.06
/499) 366 (300/476) 0.08
/9.2) 7.5 (5.6/9.4) 0.39
33.2 77.5  33.1 0.14
4 61.8 0.15
15.6 62.3  15.6 0.78
1 24.3 0.33
7 51.0 0.75
0.9 1.1  0.3 0.47
/10.2) 3.7 (1.9/9.2) 0.79
101.0 352.6  121.6 0.75
SD or median value and 25th/75th interquartile range for
okers.
Hb  hemoglobin; hs-CRP  high-sensitivity C-reactivel Stu
e-1 B
8.3 U
n 
1.7 
76.
6.5 
17.
66.
67.
54.
(11.
(313
(5.6
3.2 
67.
1.9 
21.
49.
1.1 
(1.9
1.0 
lue 
er smlasma levels were highly significantly associated with a
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Homocysteine, GPx-1, and Cardiovascular Risk May 17, 2005:1631–7.2-fold (95% CI 1.8 to 5.6; p  0.0001) increase in
ardiovascular risk. However, when formally tested, the
nteraction between GPx-1 and homocysteine did not reach
tatistical significance (p  0.16). Figure 1 displays Kaplan-
eier survival curves for patients classified into subgroups
ccording to the median value of homocysteine levels and
px-1 activity, showing a clear trend in risk from patients
ith low homocysteine/high GPx-1 to those with high
omocysteine/low GPx-1.
To assess whether these biomarkers add to the predictive
alue of traditional risk factor screening, we computed the
UC associated with models based on traditional risk
actors alone (age, diabetes, high-density lipoprotein cho-
esterol, and smoking) and compared it with the AUC
able 2. Hazards Ratio of Future Cardiovascular Events (n  11
Variable
No. of
Subjects
No. of
Events
(%)
Age- and Gende
HR (95% CI)
lutathione peroxidase-1
(U/g Hb)
42.0 159 44 (27.7) 1.00
42.0–48.3 158 28 (17.7) 0.59 (0.36–0.94)
48.3–56.3 161 20 (12.4) 0.39 (0.23–0.66)
56.3 161 20 (12.4) 0.40 (0.23–0.67)
omocysteine (mol/l)
11.3 159 11 (7.4) 1.00
11.3–13.7 152 21 (13.8) 1.71 (0.82–3.55)
13.7–16.8 153 27 (17.6) 2.18 (1.28–4.41)
16.8 151 48 (31.8) 3.76 (1.93–7.33)
reatinine (mg/dl)
0.94 157 19 (12.1) 1.00
0.94–1.04 166 20 (12.0) 0.91 (0.47–1.75)
1.04–1.19 156 23 (14.7) 1.13 (0.59–2.15)
1.19 160 50 (31.3) 2.41 (1.32–4.38)
igh-density lipoprotein
(mg/dl)
44 330 71 (21.5) 1.00
44 309 41 (13.3) 0.54 (0.37–0.80)
iabetes
No 541 48 (15.3) 1.00
Yes 98 35 (29.6) 1.71 (1.12–2.62)
moking
Never 259 35 (13.5) 1.00
Former/current 380 77 (20.3) 1.86 (1.23–2.83)
-reactive protein (mg/l)
10.1 459 73 (15.9) 1.00
10.1 154 35 (22.7) 1.41 (0.94–2.11)
tatin therapy
No 496 98 (19.8) 1.00
Yes 143 14 (9.8) 0.55 (0.31–0.96)
xtent of vessel disease
0–1 221 26 (12.2) 1.00
2 153 27 (17.0) 1.31 (0.76–2.25)
3 265 59 (22.3) 1.65 (1.03–2.64)
jection fraction (%)
40 506 63 (12.5) 1.00
40 57 26 (45.6) 4.41 (2.79–6.98)
odel 2 adjusted for age, gender, and all prognostic variables presented in the t
og-transformed), hypertension, unstable angina, history of myocardial infarction, bet
raction in high-risk patients, no adjustment on ejection fraction was performed. Fo
CI  confidence interval; Hb  hemoglobin; HR  hazard ratio.btained by adding homocysteine and GPx-1 to these risk cactors (Fig. 2). Although these (anti)oxidative biomarkers
ad significant effects when added to classic risk factors,
ingle determination added comparatively little information
o traditional risk factors in the respective models. Simul-
aneous assessment of homocysteine and GPx-1 activity
ignificantly increased the predictive value of the model
AUC 0.72 to 0.75).
ISCUSSION
n this prospective cohort of patients with documented
AD, plasma levels of homocysteine were related to future
ardiovascular events. However, this relationship was pre-
ominantly present in patients with low erythrocyte intra-
ccording to Prognostic Variables in 639 Patients
justed
Model 2
Prognostic Factors
Model 3
Fully Adjusted
Value HR (95% CI) p Value HR (95% CI) p Value
0.001 1.00 0.001 1.00 0.001
0.67 (0.41–1.10) 0.71 (0.43–1.18)
0.39 (0.21–0.70) 0.39 (0.21–0.74)
0.40 (0.22–0.72) 0.41 (0.22–0.74)
0.001 1.00 0.012 1.00 0.006
1.80 (0.83–3.90) 2.04 (0.88–4.73)
1.95 (0.92–4.14) 2.22 (0.98–5.03)
2.55 (1.23–5.30) 3.00 (1.35–6.66)
0.001 1.00 0.001 1.00 0.001
0.83 (0.40–1.72) 0.89 (0.42–1.87)
1.19 (0.59–2.42) 1.23 (0.59–2.59)
2.40 (1.23–4.67) 2.48 (1.22–5.02)
0.002 1.00 0.14 1.00 0.15
0.73 (0.48–1.11) 0.72 (0.46–1.13)
0.01 1.00 0.22 1.00 0.15
1.34 (0.84–2.12) 1.42 (0.88–2.30)
0.004 1.00 0.26 1.00 0.31
1.30 (0.82–2.07) 1.28 (0.79–2.07)
0.10 1.00 0.34 1.00 0.31
1.24 (0.80–1.91) 1.27 (0.80–2.01)
0.04 1.00 0.09 1.00 0.12
0.58 (0.31–1.09) 0.61 (0.32–1.14)
1.00 1.00
0.04 1.33 (0.74–2.40) 0.076 1.22 (0.65–2.29) 0.20
1.57 (0.92–2.66) 1.43 (0.81–2.51)
0.001 1.00 0.001 1.00 0.001
3.15 (1.87–5.29) 3.46 (1.91–6.29)
odel 3 further adjusted for body mass index, triglycerides (continuous variable,
ker therapy, and vitamin B12 and folic acid. Because of 77 missing values of ejection
ls see text.2) A
r-Ad
p




able. M
a-blocellular GPx-1 activity and hence reduced antioxidative
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f their homocysteine level was above the median value. In
atients with high GPx-1 activity, the effect associated with
levated homocysteine appeared twice lower, even though
he difference was not significant due to a small sample size,
uggesting that these patients are relatively protected against
xidative adverse effects induced by hyperhomocysteinemia.
hese results suggest that simultaneous assessment of both
iomarkers provides additional information for cardiovas-
ular risk stratification, and that interpretation of the ho-
ocysteine levels without knowledge of the GPx-1 activity
ight be misleading.
In this vein, serum creatinine was also a strong predictor
f cardiovascular risk; however, it did not increase the AUC
igure 1. Kaplan-Meier curves showing cardiovascular events in the
ubgroups of patients classified according to median baseline levels of
omocysteine (HCY) and baseline activity of glutathione peroxidase
GPx)-1.
igure 2. Hazard ratios (95% confidence interval) associated with classic
eroxidase (GPx)-1 (increase per one standard deviation) on top of classic risk
he area under the curve (AUC) of the corresponding multivariate model is pros compared with classic risk factors. It is well known that
atients even with mild to moderate impaired renal function
re at increased risk of cardiovascular complications (15).
reatinine might partly reflect the severity of vascular organ
amage as a consequence of risk factor presence; alterna-
ively, products of impaired excretion may have an addi-
ional adverse impact (16). Our findings confirm the recent
ata in mild renal impairment and can demonstrate the
redictive strength of this routine marker.
A variety of cross-sectional and retrospective case-control
tudies have provided evidence for an association between
ildly elevated plasma homocysteine and atherosclerotic
ardiovascular disease (7). The results of prospective studies,
owever, have been controversial (17,18).
Our data may, at least in part, explain the overall modest
ssociation between elevated homocysteine plasma concen-
rations and cardiovascular risk. Patients with a high anti-
xidative capacity due to increased GPx-1 activity can cope
ith the oxidative stress induced by homocysteine. Accord-
ngly, in subjects with low GPx-1 activity, homocysteine
epresents an important risk predictor for future cardiovas-
ular events, independent of vitamin B12, folic acid, and
lassic risk factors.
There is a growing body of evidence that the antioxidant
nzyme GPx-1 plays a major role in the prevention of
xidative stress induced by cardiovascular risk factors, which
enders it an important antiatherogenic enzyme. Heterozy-
ous deficiency of GPx-1 has been demonstrated to cause
ndothelial dysfunction and to induce significant structural
nd cardiac abnormalities, presumably due to increased
evels of ROS (19). Elevated homocysteine concentrations
nhibit GPx-1 activity in endothelial cells in vitro as well as
n mildly hyperhomocysteinemic mice in vivo (20,21).
eficiency of GPx-1 disturbs endothelial homeostasis in
yperhomocysteinemic mice and shows up the potentially
oxic oxidative effects of homocysteine (22). Experimental
factors in a multivariate model and with homocysteine and glutathionerisk
factors (each marker added separately to classic risk factors). In addition,
vided. HDL  high-density lipoprotein.
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Homocysteine, GPx-1, and Cardiovascular Risk May 17, 2005:1631–7tudies have elegantly demonstrated the link between cel-
ular thiol levels and reduced glutathione pools by showing
hat an increase in GPx-1 activity leads to a restoration of
ndothelial function (11). Thus, increased activity of cellular
Px-1 may rescue homocysteine-induced damages with
ar-reaching consequences if applicable in the clinical set-
ing. Because they are explorative in nature, the present
esults that the effect of homocysteine on vascular events is
odulated by GPx-1 activity have to be confirmed in large,
rospective studies that primarily address the interaction
etween homocysteine and GPx-1 activity.
From a clinical point of view, we tested our primary
ypothesis that both homocysteine and GPx-1 are likely to
dd incremental information to traditional cardiovascular
isk factors. Interestingly, despite a highly significant asso-
iation with future cardiovascular events, both markers
lone provide comparatively little additional information to
hat obtained by traditional risk factors. Interestingly, the
ffect of GPx-1 varied over time; for example, incremental
nformation on risk was observed by use of an earlier end
oint (median follow-up 4.7 years, AUC 0.72 to 0.75; data
ot shown). However, our results clearly indicate that
redictive models, including traditional risk factors like
iabetes, hypertension, smoking, age, gender, and plasma
ipid levels, and both homocysteine plasma levels and
Px-1 activity have a significantly higher likelihood ratio
nd increased AUC as compared with models including
raditional risk factors alone. Because recent data cast doubt
n the value of homocysteine as an independent predictor
or cardiovascular risk (4,23), these heterogeneous findings
ight be explained by the different antioxidative capacity.
ur findings thus support the hypothesis of the great
mportance of oxidative stress in atherosclerotic disease and
he important role of GPx-1 as a defense mechanism in this
omplex setting.
Biomarkers of oxidant stress confront clinicians with a
ubstantial diagnostic challenge, as those markers often are
t risk for auto-oxidation and tend to be unstable. In
ontrast to glutathione or lipid hydroperoxides, GPx-1 does
ot require immediate assay. So far, GPx-1 activity and
lasma homocysteine levels provide independent informa-
ion on the risk or prognosis, account for a large proportion
f the risk, are reproducible measures, and jointly add
nformation to that obtained from classic risk factors. Thus,
ome implications for patient care are fulfilled (24).
Because the activity of GPx-1 decisively determines
hether risk factors may be translated into CAD, a next
tep would be the transfer of this knowledge into clinical
ractice (25,26). Subjects with high GPx-1 activity might
rofit less from vitamin supplementation than individuals
ith lower doses of this beneficial enzyme. On the other
and, substitution of selenium might reduce homocysteine-
nduced oxidative damage in humans by increasing the
xpression and/or activity of the selen-dependent GPx-1
27,28).onclusions. In patients with CAD, the antioxidative
nzyme GPx-1 seems to protect against adverse oxidative
ffects, in part induced by homocysteine. The simultaneous
nalysis of both GPx-1 activity and plasma homocysteine
evels provides superior information on cardiovascular risk
ssessment compared with measurement of traditional risk
actors alone.
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